Clinical Hours: Mon-Fri, 8AM - 3PM(905) 493-5700
1885 Glenanna Road, Suite 220, Pickering, ON, L1V 6R6
Trillions of microbes live on healthy skin. A look at how the skin microbiome shapes eczema, psoriasis, acne, and rosacea, and what current research suggests.
The human skin hosts a remarkable ecosystem. Trillions of bacteria, fungi, viruses, and mites live on its surface in dynamic equilibrium with the immune system. Together they form the skin microbiome, an active layer of biology that contributes to barrier function, immune education, and protection against pathogens. Research over the past two decades has steadily revealed how shifts in this microbial community, a state called dysbiosis, contribute to many of the most common chronic skin conditions, from atopic dermatitis and psoriasis to acne and rosacea.
The skin microbiome refers to the collective community of microorganisms that inhabit the cutaneous surface and its appendages, including hair follicles and sweat glands. Sequencing studies have catalogued thousands of bacterial species, dozens of fungal genera, a poorly understood viral component, and arthropods such as Demodex mites. Each microenvironment of the skin, whether oily, moist, or dry, supports its own characteristic community [1].
On oily areas of the face and upper trunk, lipophilic species such as Cutibacterium acnes (formerly Propionibacterium acnes) and Malassezia yeasts dominate. Moist sites such as the axillae and groin are populated by Corynebacterium and Staphylococcus species. Dry sites of the arms and legs carry the most diverse microbial mixtures. This regional variation is more stable than its diet or hygiene reputation might suggest, with each individual maintaining a personal microbial signature over long periods [2].
The skin microbiome is not a passive layer of bystanders. Commensal organisms compete with pathogens for nutrients and attachment sites, secrete antimicrobial peptides, and engage in continuous cross-talk with skin-resident immune cells. This dialogue calibrates the immune system from infancy onward and remains an active influence throughout life.
Dysbiosis describes a shift in microbial community composition away from a state associated with health. On the skin, dysbiosis can take several forms: a loss of overall diversity, an overgrowth of a single species, the displacement of commensals by pathogens, or a change in metabolic activity even when the species list looks similar. Whatever the form, dysbiosis is increasingly recognised as a participant rather than a bystander in chronic skin disease [3].
Two important caveats apply. First, association does not prove causation; many dysbiotic patterns observed in chronic skin disease may be consequences of inflammation rather than its trigger. Second, the microbiome is shaped by genetics, age, climate, occupation, topical products, antibiotics, and systemic illness, which makes interventions difficult to isolate. The sections that follow describe what is reasonably well established for several common conditions, and where uncertainty remains.
Atopic dermatitis, also called eczema, is the chronic skin condition with the strongest and most reproducible link to the skin microbiome. During disease flares, the affected skin is colonised by Staphylococcus aureus, sometimes accounting for the majority of detectable bacteria. The overall bacterial diversity of lesional skin falls, and the protective commensal community is displaced [4].
This shift has direct clinical consequences. S. aureus produces toxins and proteases that further damage the skin barrier and amplify type 2 immune responses, the inflammatory pathway central to atopic disease. A 2017 study published in Science Translational Medicine showed that healthy human skin carries strains of coagulase-negative staphylococci such as Staphylococcus hominis that produce antimicrobial peptides capable of suppressing S. aureus. These protective strains are deficient in patients with atopic dermatitis, and reintroducing them on the skin reduced S. aureus colonisation in early human trials [5].
Standard treatment for atopic dermatitis continues to centre on restoring barrier function with emollients and controlling inflammation with topical anti-inflammatory therapy. As microbial dysbiosis improves, often after a few weeks of effective treatment, the diversity of the skin microbiome rebounds.
In psoriasis, microbiome studies have produced a more variable picture than in atopic dermatitis. Several investigations have reported reductions in overall diversity in lesional skin, with increases in Corynebacterium, Streptococcus, and certain Staphylococcus species, and decreases in Cutibacterium [6]. Whether these patterns drive disease, reflect altered skin physiology such as accelerated turnover and a thicker scale, or both, remains under investigation.
What appears well supported is that dysbiosis is part of the inflammatory context of psoriasis rather than its root cause. Genetic predisposition, immune dysregulation involving the interleukin-23 and interleukin-17 axis, and environmental triggers remain the dominant drivers. Microbiome insights are nonetheless useful, since they help explain why some patients respond unevenly to therapy and why the skin appears to be sensitised to bacterial signals.
Acne illustrates the limits of a simple good-versus-bad bacteria framework. Cutibacterium acnes is a normal resident of pilosebaceous units, and its presence alone is not sufficient to cause disease. Strain-level studies have demonstrated that healthy skin and acne-affected skin carry different phylotypes of C. acnes, and that overall diversity within follicles, not the mere presence of the species, distinguishes the two states [7].
Inflammation in acne is driven by the interaction between specific C. acnes lineages, sebum composition, follicular keratinisation, and host immune responses. This framework explains why broad-spectrum topical antibiotics, while still useful for some patients, are increasingly being supplanted by therapies that modify the follicular environment rather than attempt to sterilise it.
Rosacea highlights a frequently overlooked component of the skin microbiome: the resident mite Demodex folliculorum. Demodex is a normal inhabitant of facial pilosebaceous units in adults, but its density is markedly elevated in many patients with papulopustular rosacea. The associated bacterium Bacillus oleronius, carried by Demodex, has been implicated in stimulating inflammatory responses in susceptible individuals [8].
Treatments that reduce Demodex density, such as topical ivermectin, have become a mainstay for inflammatory rosacea, reflecting the modern view that rosacea management often requires addressing the skin's microbial ecology alongside its vascular and inflammatory components.
Research interest in microbiome-targeted therapies for chronic skin disease is intense, but the clinical reality remains modest. Topical and oral probiotics, postbiotics (bioactive products of bacterial metabolism), and live biotherapeutic products are being investigated for atopic dermatitis, acne, and other conditions. Some early studies suggest benefits in symptom severity and quality of life, but high-quality randomised trials remain few in number, and product formulations are highly variable [3].
Several practical points are reasonably well supported by current evidence:
The skin microbiome is an active partner in skin health, not a passive cover. Chronic conditions such as eczema, psoriasis, acne, and rosacea are now understood as disorders in which microbial communities, host genetics, barrier function, and immune regulation all interact. This integrated view explains why no single intervention reliably resolves these conditions, and why durable improvement usually requires layered treatment.
For patients with chronic or recurrent skin disease, an individualised assessment from a dermatologist is the appropriate first step. The Centre for Medical and Surgical Dermatology offers a comprehensive dermatology consultation and ongoing prescription management for inflammatory skin disease, including dedicated specialty care for immune-mediated skin conditions. Recent advances in microbiome science do not replace these foundations of care, but they help explain why thoughtful, individualised treatment outperforms quick fixes.
For broader context on barrier biology and the related concept of the gut-skin axis, a companion article on leaky gut and leaky skin examines the evidence and the hype in more depth.
This article is intended for educational purposes and does not replace professional medical advice. Please consult your dermatologist for personalized recommendations.
Your feedback helps us improve our news and clinical insights
From medical dermatology to surgical procedures, our clinic provides comprehensive care for all skin, hair, and nail conditions.